An overall summary of AEs, SAEs, and Regadenoson-emergent AEs will be presented, coded using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class and preferred term.

The number of patients with changes in physical examination status from normal at baseline to abnormal at each post-administration time point will be summarized.

The occurrence of post-administration vital sign values outside the normal limits will be summarized.

The occurrence of post-administration vital sign values outside the normal limits will be summarized.

The occurrence of post-administration vital sign values outside the normal limits will be summarized.

The occurrence of post-administration body temperature values outside the normal limits will be summarized by counts and percentages by age group and actual dose.

Descriptive statistics will be used to describe the observed values and change from baseline for ECG intervals (RR, QT, QTcF\[Fridericia\])

The occurrence of post-administration clinical laboratory values outside the normal limits will be summarized.

Blood samples for PK assessment will be collected and processed for measurement of Regadenoson blood concentrations. Concentration-time profiles will be evaluated using compartmental methods and a population approach with mixed-effect modelling. A summary will be listed by patient and summarized by age group and actual dose at each time point.